News Stories

MIAMI, Fla. – (May 18, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions.

Newly Defined Term Lipid Specialist Aims to Formalize Medical Specialty, Enhance Public Understanding of Blood Fat Disorders and Optimal Treatment

Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the U.S. Food and Drug Administraion (FDA) has approved Praluent®  (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.